Cart contains    items

Browse by molecule: [A]  [B]  [C]  [D]  [E]  [F]  [G]  [H]  [I]  [J]  [K]  [L]  [M]  [N]  [O]  [P]  [Q]  [R]  [S]  [T]  [U]  [V]  [W]  [X]  [Y]  [Z]  

Mouse VEGF 120AA Recombinant (E.Coli)


accession:  Q00731
   Size A     2ug   $ 70
   Size B      10ug  $160
   Size C      1mg  $ 3500
Domain  :  four helical cytokine core
Gene  :  VEGF
Catalog no. :  RKQ007311
Optimized DNA sequence encoding Mouse Vascular Endothelial Growth Factor mature chain was expressed in Escherichia Coli.

Molecular weight:

Native mouse VEGF-120 is generated by the proteolytic removal of the signal peptide and propeptide, the molecule has a calculated molecular mass of approximately 14 kDa.

Recombinant Vascular endothelial growth factor is a disulfide-linked homodimer protein consisting of 121 amino acid residue subunits, and migrates as an approximately 28 kDa protein under non-reducing and as 14kDa under reducing conditions in SDS-PAGE.

>96%, as determined by SDS-PAGE and HPLC

Biological Activity:
The ED(50) was determined by the dose-dependent proliferation of human umbilical vein endothelial cells and was found to be in the range of 2.0-4.0 ng/ml.

Protein Sequence:
        10         20         30         40         50         60 

        70         80         90        100        110        120 

       130        140        
(*)Complete precursor sequence shown, expressed chain highlighted
Endotoxin content was assayed using a LAL gel clot method.
Endotoxin level was found to be less than 0.1 ng/µg(1EU/µg).

Mouse VEGF-120 was lyophilized from a 0.2 μm filtered solution in 2.5% glycine, 0.5% sucrose, 0.01% Tween80, 5 mM Glutamic acid, pH 4.5.

A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/mL. This solution can then be diluted into other buffers.

The lyophilized protein is stable for at least 2 years from date of receipt at -20° C.
Upon reconstitution, this cytokine can be stored in working aliquots at 2° - 8° C for one month, or at -20° C for six months, with a carrier protein without detectable loss of activity.

Avoid repeated freeze/thaw cycles.

This cytokine product is for research purposes only.It may not be used for therapeutics or diagnostic purposes.



VEGF is a homodimeric heavily glycosylated protein.The human factor occurs in several molecular variants of 121, 162, 145, 148, 165, 183, 189 , 206 amino acids, arising by alternative splicing of the mRNA.The splice forms of VEGF differ in biological properties such as the receptor types, which they recognize and their interaction with heparan sulfate proteoglycans. The 165 amino acid form of the factor is the most common form in most tissues. Kaposi sarcomas express VEGF121 and VEGF165. VEGF121 and VEGF165 are soluble secreted forms of the factor while VEGF189 and VEGF206 are mostly bound to heparin-containing proteoglycans in the cell surface or in the basement membrane. A high-affinity glycoprotein receptor of 170-235 kDa is expressed on vascular endothelial cells. The interaction of VEGF with heparin-like molecules of the extracellular matrix is required for efficient receptor binding. Protamine sulfate and suramin are capable of replacing the receptor-bound factor. The high-affinity receptor for VEGF, now known as VEGFR1, has been identified as the gene product of the FLT-1. Another receptor for VEGF, now known as VEGFR2, is KDR, also known as FLK-1. A factor that competes with the 165 amino acid form of VEGF for receptor binding is PLGF. A third receptor type, VEGFR3 is known also as FLT- 4. An isoform-specific receptor for VEGF165 has been identified as human Neuropilin-1.

Related Publications:
decreased nephrin and glepp-1, but increased VEGF, flt-1, and nitrotyrosine, expressions in kidney tissue sections from women with preeclampsia
Reproductive Sciences, Oct 2009; 16: 970 - 979.
significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer
Ann. Onc., Oct 2009; 20: 1639 - 1646.
comparative analysis of metastasis variants derived from human prostate carcinoma cells: roles in intravasation of VEGF-mediated angiogenesis and upa-mediated invasion
Am. J. Pathol., Oct 2009; 175: 1638 - 1652.
autocrine loop between vascular endothelial growth factor (VEGF)-c and VEGF receptor-3 positively regulates tumor-associated lymphangiogenesis in oral squamoid cancer cells
Am. J. Pathol., Oct 2009; 175: 1709 - 1721.
polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes (poems) syndrome refractory to complete serum vascular endothelial growth factor (VEGF) blockade: insights from sequential VEGF monitoring
NDT Plus, Oct 2009; 2: 357 - 359.

by class:
Growth factors
CD markers
Viral Antigens
by species:
Purified Polyclonal
Related Products:
product_icon_7.jpg Rabbit anti VEGF Polyclonal
product_icon_7.jpg Monoclonal mouse anti human VEGF
product_icon_8.jpg Human VEGF 165AA Recombinant (E.Coli)
product_icon_8.jpg Mouse VEGF 164AA Recombinant (E.Coli)
product_icon_8.jpg Human Endocrine Gland Vascular Endothelial Growth Factor Recombinant
product_icon_8.jpg Mouse VEGF 120AA Recombinant (E.Coli)
product_icon_8.jpg Human VEGF 165AA Recombinant (CHO Cell)
product_icon_8.jpg Mouse VEGFR2 Recombinant, Fc
product_icon_8.jpg Mouse VEGFR2 Recombinant
product_icon_8.jpg Human VEGFR2 Recombinant, Fc
product_icon_8.jpg Human VEGFR2 Recombinant
product_icon_8.jpg Mouse VEGF 164AA Recombinant (CHO Cell)
product_icon_8.jpg Human VEGF 121AA Recombinant (CHO Cell)
product_icon_8.jpg Human VEGF 165AA Recombinant (CHO Cell), Biotinylated
product_icon_8.jpg Human VEGF 121AA Recombinant (CHO Cell), Biotinylated
product_icon_7.jpg Rabbit anti VEGFR2 Polyclonal
Item name Size Quantity Price(USD) Remove
Cart Total $